Cancer Immunotherapy – Harnessing the immune system to battle cancer
The approval of imatinib, a type of cancer growth blocker called ‘tyrosine kinase inhibitor’ twenty years ago, was considered to be “the birth of precision medicine” by Louis DeGennaro, President and CEO of The Leukemia & Lymphoma Society. A decade later, the U.S. Food and Drug Administration approved ipilimumab, the […]
Continue Reading
